Entrada reports Q3 2026 results, DMD trials advance across multiple cohorts

Entrada Therapeutics reported third quarter 2026 financial results on November 5, 2026, alongside updates across its Duchenne muscular dystrophy (DMD) pipeline.

In the ELEVATE-44-201 study, all Cohort 1 participants completed their final dose during the open-label period and have moved into the long-term extension study.¹ The company expects data from the Cohort 1 open-label period by year-end 2026.¹ For Cohort 2 (12 mg/kg), enrollment is complete and dosing is ongoing, with data expected in the first quarter of 2027.¹ For Cohort 3 (18 mg/kg), an independent Data Monitoring Committee reviewed safety data in October 2026 and recommended starting the cohort at the highest planned dose, with enrollment now underway.¹

In the ELEVATE-45-201 study, the company reported positive Cohort 1 data in October 2026 from a global Phase 1/2 study of ENTR-601-45, in which participants received three doses of 5 mg/kg or placebo and the study met its primary objectives of favorable safety and tolerability.¹ Headache was the most common treatment-emergent adverse event, and one participant had two serious adverse events, vomiting and pyrexia, that later resolved, with no discontinuations.¹ All Cohort 1 participants have advanced to the open-label Phase 2 portion, where they will receive six doses of 5 mg/kg.¹ Cohort 2 enrollment is complete, with data expected in the first half of 2027.¹ In October 2026, the FDA's Office of Orphan Products Development granted orphan drug designation to ENTR-601-45 for DMD.¹

Partner Vertex has completed enrollment and dosing in the MAD portion of the GALILEO Phase 1/2 trial of VX-670 in myotonic dystrophy type 1, with interim results expected in the second half of 2026.¹

On finances, cash, cash equivalents and marketable securities totaled $193.0 million as of September 30, 2026, down from $295.7 million at the end of 2025.¹ The company said this is expected to fund operations into the fourth quarter of 2027.¹